Fundamentals and applications of nanoparticles for ultrasound‐based imaging and therapy

A Review on Ultrasound-based Methods to Image the Distribution of Magnetic Nanoparticles in Biomedical Applications

Magnetic nanoparticles (MNPs) have gained significant attention in biomedical engineering and imaging applications due to their unique magnetic and mechanical properties. With their high magnetization and small size, MNPs serve as excitation sources for magnetically heating to destroy tumors (magnetic hyperthermia) and magnetically controlled drug carriers in magnetic drug targeting. However, effectively visualizing the distribution of MNPs during research or potential clinical use with low-cost modalities remains a critical challenge. Although magnetic resonance imaging provides pre- and post-procedural imaging, it is considered to be high cost, and real-time imaging during clinical procedures is limited. In contrast, ultrasound-based imaging methods offer the advantage of providing the potential for immediate feedback during clinical use and are considered to be a low-cost modality. Ultrasound-based imaging techniques, including magnetomotive ultrasound, magnetoacoustic tomography, and thermoacoustic imaging, emerged as promising approaches for imaging the distribution of MNPs. These techniques offer the potential for real-time imaging, facilitating precise therapy monitoring. By exploring the strengths and limitations of various ultrasound-based imaging techniques for MNPs, this review seeks to provide comprehensive insights that can guide researchers in selecting suitable ultrasound-based modalities and inspire further advancements in this exciting field.

Nanomedicine and clinical diagnostics part I: applications in conventional imaging (MRI, X-ray/CT, and ultrasound)

Integrating nanotechnologies in diagnostic imaging presents a promising step forward compared to traditional methods, which carry certain limitations. Conventional imaging routes, such as X-ray/computed tomography and magnetic resonance imaging, derive significant advantages from nanoparticles (NPs), which allow researchers and clinicians to overcome some of the limitations of traditional imaging agents. In this literature review, we explore recent advancements in nanomaterials being applied in conventional diagnostic imaging techniques by exploring relevant reviews and original research papers (e.g. experimental models and theoretical model studies) in the literature. Collectively, there are numerous nanomaterials currently being examined for use in conventional imaging modalities, and each imaging technique has unique NPs with properties that can be manipulated to answer an array of clinical questions specific to that imaging modality. There are still challenges to consider, including getting regulatory approval for clinical research and routine use about long-term biocompatibility, which collectively emphasize the need for continued research to facilitate the integration of nanotechnology into routine clinical practice. Most importantly, there is a continued need for strong, collaborative efforts between researchers, biomedical engineers, clinicians, and industry stakeholders, which are necessary to bridge the persistent gap between translational ideas and implementation in clinical settings.

Dextran-Encapsulated Nanoparticles and Super-Nanoparticle Assemblies: Preparation from Quantum Dots, Fluorescent Polymers, and Magnetic Nanoparticles for Application to Cellular Immunolabeling

Nanoparticles (NPs) continue to be developed as labels for bioanalysis and imaging due to their small size and, in many cases, emergent properties such as photoluminescence (PL) and superparamagnetism. Some applications stand to benefit from amplification of the advantageous properties of a NP, but this amplification is not a simple matter of scaling for size-dependent properties. One promising approach to amplification is, therefore, to assemble many copies of a NP into a larger but still nanoscale and colloidal entity. Here, we use multiple types of hydrophobic nanocrystal to show that amphiphilic dextran is a versatile material for the preparation and surface functionalization of such super-NP assemblies: CdSe/CdS/ZnS quantum dots (QDs), InP/ZnS QDs, and Si QDs; iron oxide magnetic NPs (MNPs); composites of QDs and MNPs; and composites of QDs and MNPs with fluorene-based and phenylenevinylene-based conjugated polymers. The amphiphilic dextran was also useful for the preparation of conjugated polymer NPs (CPNs) without the inclusion of inorganic nanocrystals. The prepared super-NPs and CPNs were characterized, physically and photophysically, at both the ensemble and the single-particle levels. Per colloidal entity, the super-QDs were orders of magnitude brighter than the individual QDs. This enhancement enabled assemblies of nominally more benign InP/ZnS and Si QDs to be competitive alternative materials to CdSe/CdS/ZnS QDs, which are normally much brighter when compared as individual nanocrystals. The dextran functionalization imparted low nonspecific binding and enabled the use of tetrameric antibody complexes (TACs) for simple and selective immunolabeling of cells with all of the prepared super-NP, CPN, and composite materials. Labeling with the super-QDs provided significantly enhanced PL signals, the super-MNPs enabled magnetic pull-down of cells, and both capabilities were concurrently available with composite assemblies. Overall, this study demonstrates that the preparatory method and functional benefits of amphiphilic dextran extend to a range of hydrophobic materials and combinations thereof. There is strong potential for assembling a diverse set of property-amplified designer labels that are ready-made for in vitro applications in bioanalysis and imaging.

Quantifying nanoparticle delivery: challenges, tools, and advances

This review explores challenges and methods for quantifying nanoparticle delivery in therapeutic applications. We discuss three main approaches: (1) functional readouts that assess therapeutic effects post nanoparticle administration, (2) nanocarrier tracking that directly monitors the nanoparticle localization, and (3) cargo tracking that infers nanoparticle localization by measuring encapsulated agents or attached surface tags. Reanalysis of the Wilhelm et al. Cancer Nanomedicine Repository dataset found mixed quantification methodologies, which could cause misleading conclusions. We discuss potential pitfalls in each quantification approach and highlight recent advancements in novel technologies. It is important that researchers select appropriate quantification methods based on their objectives and consider integrating multiple approaches for a comprehensive understanding of in vivo nanoparticle behavior to facilitate their clinical translation.

Nanotheranostics: Molecular Diagnostics and Nanotherapeutic Evaluation by Photoacoustic/Ultrasound Imaging in Small Animals

Nanotheranostics is a rapidly developing field that integrates nanotechnology, diagnostics, and therapy to provide novel methods for imaging and treating wide categories of diseases. Targeted nanotheranostics offers a platform for the precise delivery of theranostic agents, and their therapeutic outcomes are monitored in real-time. Presently, in vivo magnetic resonance imaging, fluorescence imaging, ultrasound imaging, and photoacoustic imaging (PAI), etc. are noninvasive imaging techniques that are preclinically available for the imaging and tracking of therapeutic outcomes in small animals. Additionally, preclinical imaging is essential for drug development, phenotyping, and understanding disease stage progression and its associated mechanisms. Small animal ultrasound imaging is a rapidly developing imaging technique for theranostics applications due to its merits of being nonionizing, real-time, portable, and able to penetrate deep tissues. Recently, different types of ultrasound contrast agents have been explored, such as microbubbles, echogenic exosomes, gas-vesicles, and nanoparticles-based contrast agents. Moreover, an optical image obtained through photoacoustic imaging is a noninvasive imaging technique that creates ultrasonic waves when pulsed laser light is used to expose an object and creates a picture of the tissue's distribution of light energy absorption on the object. Contrast agents for photoacoustic imaging may be endogenous (hemoglobin, melanin, and DNA/RNA) or exogenous (dyes and nanomaterials-based contrast agents). The integration of nanotheranostics with photoacoustic and ultrasound imaging allows simultaneous imaging and treatment of diseases in small animals, which provides essential information about the drug response and the disease progression. In this review, we have covered various endogenous and exogenous contrast agents for ultrasound and photoacoustic imaging. Additionally, we have discussed various drug delivery systems integrated with contrast agents for theranostic application. Further, we have briefly discussed the current challenges associated with ultrasound and photoacoustic imaging.

Hybrid Nanoplatforms Comprising Organic Nanocompartments Encapsulating Inorganic Nanoparticles for Enhanced Drug Delivery and Bioimaging Applications

Organic and inorganic nanoparticles (NPs) have attracted significant attention due to their unique physico-chemical properties, which have paved the way for their application in numerous fields including diagnostics and therapy. Recently, hybrid nanomaterials consisting of organic nanocompartments (e.g., liposomes, micelles, poly (lactic-co-glycolic acid) NPs, dendrimers, or chitosan NPs) encapsulating inorganic NPs (quantum dots, or NPs made of gold, silver, silica, or magnetic materials) have been researched for usage in vivo as drug-delivery or theranostic agents. These classes of hybrid multi-particulate systems can enable or facilitate the use of inorganic NPs in biomedical applications. Notably, integration of inorganic NPs within organic nanocompartments results in improved NP stability, enhanced bioavailability, and reduced systemic toxicity. Moreover, these hybrid nanomaterials allow synergistic interactions between organic and inorganic NPs, leading to further improvements in therapeutic efficacy. Furthermore, these platforms can also serve as multifunctional agents capable of advanced bioimaging and targeted delivery of therapeutic agents, with great potential for clinical applications. By considering these advancements in the field of nanomedicine, this review aims to provide an overview of recent developments in the use of hybrid nanoparticulate systems that consist of organic nanocompartments encapsulating inorganic NPs for applications in drug delivery, bioimaging, and theranostics.

Image-guided drug delivery in nanosystem-based cancer therapies

The past decades have shown significant advancements in the development of solid tumor treatment. For instance, implementation of nanosystems for drug delivery has led to a reduction in side effects and improved delivery to the tumor region. However, clinical translation has faced challenges, as tumor drug levels are still considered to be inadequate. Interdisciplinary research has resulted in the development of more advanced drug delivery systems. These are coined "smart" due to the ability to be followed and actively manipulated in order to have better control over local drug release. Therefore, image-guided drug delivery can be a powerful strategy to improve drug activity at the target site. Being able to visualize the inflow of the administered smart nanosystem within the tumor gives the potential to determine the right moment to apply the facilitator to initiate drug release. Here we provide an overview of available nanosystems, imaging moieties, and imaging techniques. We discuss preclinical application of these smart drug delivery systems, the strength of image-guided drug delivery, and the future of personalized treatment.

Bridging the In Vitro to In Vivo gap: Using the Chick Embryo Model to Accelerate Nanoparticle Validation and Qualification for In Vivo studies

We postulate that nanoparticles (NPs) for use in therapeutic applications have largely not realized their clinical potential due to an overall inability to use in vitro results to predict NP performance in vivo. The avian embryo and associated chorioallantoic membrane (CAM) has emerged as an in vivo preclinical model that bridges the gap between in vitro and in vivo, enabling rapid screening of NP behavior under physiologically relevant conditions and providing a rapid, accessible, economical, and more ethical means of qualifying nanoparticles for in vivo use. The CAM is highly vascularized and mimics the diverging/converging vasculature of the liver, spleen, and lungs that serve as nanoparticle traps. Intravital imaging of fluorescently labeled NPs injected into the CAM vasculature enables immediate assessment and quantification of nano-bio interactions at the individual NP scale in any tissue of interest that is perfused with a microvasculature. In this review, we highlight how utilization of the avian embryo and its CAM as a preclinical model can be used to understand NP stability in blood and tissues, extravasation, biocompatibility, and NP distribution over time, thereby serving to identify a subset of NPs with the requisite stability and performance to introduce into rodent models and enabling the development of structure-property relationships and NP optimization without the sacrifice of large populations of mice or other rodents. We then review how the chicken embryo and CAM model systems have been used to accelerate the development of NP delivery and imaging agents by allowing direct visualization of targeted (active) and nontargeted (passive) NP binding, internalization, and cargo delivery to individual cells (of relevance for the treatment of leukemia and metastatic cancer) and cellular ensembles (e.g., cancer xenografts of interest for treatment or imaging of cancer tumors). We conclude by showcasing emerging techniques for the utilization of the CAM in future nano-bio studies.